NOVOZYMES A/S SPONS.ADR 1 (NZM) — Financial Flexibility Index

Latest as of March 2026: 0.05x

NOVOZYMES A/S SPONS.ADR 1 (NZM) has a Financial Flexibility Index of 0.05x as of March 2026. Free cash flow of €260.20 Million (operating CF €167.10 Million minus capex €93.10 Million) represents 0% of total liabilities (€5.60 Billion). Also explore NZM net asset momentum to track the company's year-over-year net asset growth rate.

Financial Flexibility Index

0.05x
Free Cash Flow / Total Liabilities

Free Cash Flow

€260.20 Million
Operating CF − Capex

Total Liabilities

€5.60 Billion
EUR

Capital Expenditures

€93.10 Million
EUR

NOVOZYMES A/S SPONS.ADR 1 Financial Flexibility Index (2021–2025)

Historical Financial Flexibility Index trend for NOVOZYMES A/S SPONS.ADR 1 across 5 annual periods. Check NZM asset resilience ratio to evaluate the company's liquid asset resilience ratio.

Annual Financial Flexibility Index for NOVOZYMES A/S SPONS.ADR 1 (2021–2025)

Year-by-year free cash flow to debt coverage for NOVOZYMES A/S SPONS.ADR 1. For the full company profile including market capitalisation, see NOVOZYMES A/S SPONS.ADR 1 (NZM) total market value.

Year Flexibility Index Free Cash Flow (EUR) Operating CF Total Liabilities YoY Change
2025 0.31x €1.69 Billion €1.22 Billion €5.49 Billion ▼ -10.3%
2024 0.34x €1.38 Billion €1.02 Billion €4.02 Billion ▼ -22.4%
2023 0.44x €832.90 Million €557.10 Million €1.88 Billion ▼ -11.8%
2022 0.50x €925.52 Million €537.65 Million €1.85 Billion ▲ +18.8%
2021 0.42x €712.90 Million €546.17 Million €1.69 Billion
Financial Flexibility Index = (Operating CF − Capex) / Total Liabilities = Free Cash Flow / Total Liabilities